None
Quote | Hemispherx BioPharma Inc. (NYSE:HEB)
Last: | $ |
---|---|
Change Percent: | -0.55% |
Open: | $1.97 |
Close: | $1.80 |
High: | $1.97 |
Low: | $1.78 |
Volume: | 14,934 |
Last Trade Date Time: | 09/02/2019 04:51:01 pm |
News | Hemispherx BioPharma Inc. (NYSE:HEB)
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...
Hemispherx Biopharma (NYSEMKT: HEB ): Q2 GAAP EPS of -$1.07 beats by $0.65 . Cash, cash equivalents and marketable securities of $2.86B Shares +3.8% Press Release More news on: Hemispherx Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, ,
Message Board Posts | Hemispherx BioPharma Inc. (NYSE:HEB)
Subject | By | Source | When |
---|---|---|---|
Hemispherx Biopharma ($HEB) | mick | investorshub | 11/05/2020 3:36:39 PM |
I liked the original name better lol. Still | Richard2 | investorshub | 11/05/2020 2:30:40 PM |
Hemispherx Biopharma (HEB)$ NOW $AIM | mick | investorshub | 04/05/2020 8:08:00 PM |
Thank you Richard, I couldn't seem to find | deniseann | investorshub | 02/05/2020 4:37:21 PM |
$AIM is the new ticker. | Richard2 | investorshub | 02/05/2020 9:43:25 AM |
News, Short Squeeze, Breakout and More Instantly...
Hemispherx BioPharma Inc. Company Name:
HEB Stock Symbol:
NYSE Market:
Hemispherx BioPharma Inc. Website:
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...
OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the ...
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovar...